Acadia pharmaceuticals reports second quarter 2022 financial results

San diego--(business wire)--acadia pharmaceuticals inc. (nasdaq: acad), today announced its financial results for the second quarter ended june 30, 2022. “in the second quarter of 2022, nuplazid net sales increased 17% year-over-year,” said steve davis, chief executive officer. “last month, we submitted an nda for our second potential commercial product, trofinetide which would be the first fda-approved treatment for rett syndrome. together with a strong balance sheet, our late and early-stage
ACAD Ratings Summary
ACAD Quant Ranking